Glioblastomas are the most common primary brain tumors. Despite aggressive resection, radiotherapy and concomitant chemotheraphy overall survival is 14-16 months, and 5 year survivial rate is only 2%. The poor prognosis required development of new treatment modalities. Tumor Treating Fields, molecularly targetted drugs, antiangiogenic molecules, immune checkpoint inhibitors, tumor vaccines, Chimeric Antigen Receptor-T cell, viral theraphy and oncolytic viruse and mesenchymal stem cell vectors are some of the modalities that are currently being developed.

Keywords: Glioblastoma, TTF, tumor treating fields, viral oncolysis, immune check point inhibitors, CAR-T, mesenchymal stem cells